Edgewise Therapeutics, Inc. (NASDAQ:EWTX – Get Free Report) shares hit a new 52-week high during mid-day trading on Thursday after Truist Financial raised their price target on the stock from $25.00 to $33.00. Truist Financial currently has a buy rating on the stock. Edgewise Therapeutics traded as high as $27.51 and last traded at $26.37, with a volume of 2109692 shares changing hands. The stock had previously closed at $19.07.
EWTX has been the topic of several other research reports. Piper Sandler reaffirmed an “overweight” rating and set a $48.00 target price on shares of Edgewise Therapeutics in a research report on Monday, July 1st. Wedbush reiterated an “outperform” rating and issued a $31.00 target price on shares of Edgewise Therapeutics in a research note on Friday, August 16th. JPMorgan Chase & Co. raised their price target on shares of Edgewise Therapeutics from $30.00 to $31.00 and gave the company an “overweight” rating in a research report on Monday, August 12th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $32.00 price objective on shares of Edgewise Therapeutics in a research report on Tuesday. Five research analysts have rated the stock with a buy rating, According to MarketBeat, Edgewise Therapeutics currently has an average rating of “Buy” and an average price target of $35.00.
Check Out Our Latest Stock Report on Edgewise Therapeutics
Institutional Trading of Edgewise Therapeutics
Edgewise Therapeutics Trading Down 4.1 %
The stock has a market cap of $2.64 billion, a PE ratio of -18.25 and a beta of 0.15. The business has a 50-day moving average price of $18.99 and a 200 day moving average price of $18.12.
Edgewise Therapeutics (NASDAQ:EWTX – Get Free Report) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.36) by $0.02. On average, equities analysts predict that Edgewise Therapeutics, Inc. will post -1.48 earnings per share for the current year.
About Edgewise Therapeutics
Edgewise Therapeutics, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy.
Further Reading
- Five stocks we like better than Edgewise Therapeutics
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut
- How Can Investors Benefit From After-Hours Trading
- FedEx Stock Dips: Another Reason to Fear Recession Is Near
- Where to Find Earnings Call Transcripts
- The Half-Penny Revolution: Will SEC’s Reform Benefit Investors?
Receive News & Ratings for Edgewise Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edgewise Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.